Patients with advanced esophageal adenocarcinoma who respond to neoadjuvant chemotherapy show a significant survival benefit after resection.
Therefore, prediction of response before treatment is desirable.
Dr Theisen and colleagues from Germany assessed genetic predictors of response and survival for patients with esophageal adenocarcinoma prior to neoadjuvant therapy.
The team identified 32 patients with advanced esophageal adenocarcinoma who underwent neoadjuvant therapy with resection of their tumor.
The research team evaluated thymidylate synthase, excision repair cross complementing and Gluthatione S-transferase mRNA levels prior to the treatment.
These results were analyzed in terms of response and survival.
|17 patients had at least 1 gene expression|
|Diseases of the Esophagus|
The researcher reported that 18 patients responded to this protocol.
Of these, 17 patients demonstrated a gene expression level at or below the respective median of at least 1 gene.
This had a profound impact on survival, demonstrating an increase in survival for patients who have thymidylate synthase, excision repair cross complementing, or Gluthatione S-transferase mRNA level at or below the median.
Dr Theisen’s team concluded, “These results demonstrate a potential predictive value of a gene expression profile available prior to therapy.”
“These data have to be confirmed by a larger prospective trial.”